# Amgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 win

> **Newsylist Open Intelligence Dossier** · First detected: 2026-09-22 21:29 UTC · Category: Business · Sources: 10 · Current Velocity: 7.91

## Intelligence Brief
"Amgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 win" developed substantial multi-source reporting across the Business sector, tracked across 10 distinct newsrooms by Newsylist.


Key reporting was led by Yahoo, FirstWord, Kalkine Media and GuruFocus. Coverage velocity and cross-outlet momentum were measured using Newsylist open coverage telemetry.


Synthesized from multi-source international reporting and live coverage telemetry under Newsylist open intelligence methodology.

## Verified Facts & Key Claims
### What drove coverage for Amgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 w?
Coverage spiked when 10 independent newsrooms published 10 verified reports during this coverage cycle.

### How did Newsylist track this trend?
Newsylist monitored article arrival rates, source diversity, and cross-outlet validation in real time.

## Key People, Organizations & Locations
Amgen, Horizon-acquired

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| Yahoo | First of Amgen’s Phase III Sjögren’s disease trials succeeds | 2026-09-22 14:20 | [Source Link](https://news.google.com/rss/articles/CBMiiwFBVV95cUxOTDVLUWtqTlFielJtZFpKdk90bkoyNFNrUlJHcFpUYm5zZjdJZ1VEQmJzcDZaNHhKekY0c0RlczQya1RKVEJadmxWc3E4a3RvZFhocW9URklLYzVISmlCb29FQzVqN3BMYV9ESGROY3FqWE1FQndjWTFqck9BYVpld1EwUEhPYXJrYmtZ?oc=5) |
| FirstWord | Amgen's Horizon-sourced fusion protein succeeds in late-stage Sjögren's study | 2026-09-22 14:20 | [Source Link](https://news.google.com/rss/articles/CBMiU0FVX3lxTE82R3Q4VW05NFFRdUJUTkJjV3BUT2pkcUo3Y1lkUl9tbWp4eHdacW5PN2loNUlwbzdHbjZZUl9fSG41Q2ZOLUdyUXQwSllydlA0SmYw?oc=5) |
| Kalkine Media | What is changing in the investment case for Amgen (NASDAQ:AMGN)? | 2026-09-22 14:20 | [Source Link](https://news.google.com/rss/articles/CBMiqgFBVV95cUxPekdSRzVDMzJjaU8yY3lxcThsaDhEbXV3MktDN2dUUTh6V2lXUENsVFo0VEp2VHFiNWJyNlpRUG10Wi1Pd3FhNm53UmxxWFJBRC1ESklfU1ViSE1uVlJkTzVWcktwV21pckdtbThzOW43cU9HbmhxUTRGN0VpVjV5MFQyT2ZDMHlJMkJuNm1hLWhjN05MSW50cFZPRlBfNlF3SG5fTVduSHZFUQ?oc=5) |
| GuruFocus | Is Amgen Inc (AMGN) Overvalued After 4.3% Rally? GF Value Says O | 2026-09-22 14:20 | [Source Link](https://news.google.com/rss/articles/CBMiqwFBVV95cUxOLUptdFhYdXBMMFkwOXp1RW5EMUU1VkxSU1hNeHpBRmI5RWpXUmtUV1BKSFo1Nzd4czg5Rl9TTTV3VXBvNVFpSkFhZWNvYlVoc2JTYVg5YW9seWxrUnpOd2VXQ0R5T0tBcVlKQmRiLTc2ejY4aE82Y2o1WkVhN2ZZTmdlU3J4RXhhOTRxZDRTbkEzVVh0WGFETm1nMjFoQ0MwQkNMTWRfUVlaYjQ?oc=5) |
| Amgen | AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE | 2026-09-22 14:20 | [Source Link](https://news.google.com/rss/articles/CBMi9gFBVV95cUxOSHh6ZEExVXFEZHYyVnB3TTFwRnctZ2RqRVpBd0xGSFlVWnlxZDctUU9LN2hSVURzSkYtMHN3dVM0V1V1eU5rcnJpVE1Gek96QmlvU0I0N2Z2c2s0emtOOFBSX3NSa2RCZmthRlVkR2pOb0U3eWRRc0JDYWd4X05CanVwdkFtUkpqc1AxT3JtNU5lZGd6YjR4UDRlWHhzZE9fZkpWTU4tNVhrWlZmX3B5ZFdwdDVlRndJODE5dGdQSnlqV2p3OFdhRlNqMm9Za19hMlJENEVVaXVKSW9Wbm1IeHFDV0VaMVRUdkhoa01oNlFhdHloZWc?oc=5) |
| Investor's Business Daily | Amgen Boasts Success In Sjogren's; Shares Bound Higher | 2026-09-22 14:20 | [Source Link](https://news.google.com/rss/articles/CBMiigFBVV95cUxOY3QycHltLTVCUW1NTUJ2eERIWWlfcUZUMnpFX1ZUaXdibWtodnVRd3RTTVNlMEFLa3JzeGg3UTk0SHZPZ29UTWtXOGwtMzMtckVpSmNsa3QzQ2RLWmx1R0pmeVEyek9PTWYwZE8zNWFwQVNZLXVRaWRNTkg1NDJTekdidWgydmFtSmc?oc=5) |
| PR Newswire | AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE | 2026-09-22 14:20 | [Source Link](https://news.google.com/rss/articles/CBMi_AFBVV95cUxORkE0THhhQXo2aVVlbW9yVm5EcFVtc2VzeFJUS0YyQVhRNmdmcjJoNVZzdENNZ1FFQ2tiNlVERUhEaUtJdEFZZk1oaGJTVnpVU0VKOU1VMEljTzl3bVkxZlF2cDdGT29xZUlNNHFNZXJFSEFDdW1SWmZMbGFZVHRrUktORnRpOXZsNEJCc2ExMXV4b0h3TVcwakhTdERNcV9iVzlKUzJzU05UR3NJN3d6Yk5ObkpBZzhhcjZ2c1E5UVZfbDRVMURZYmhwdkJSZE1jYUlVaElzQWZwY3lnOHNpTEQ4bFdxVnVIUUhiRDNESE95SWlVNTVkdURJSDc?oc=5) |
| endpoints.news | Amgen’s Phase 3 Sjögren’s win; Novartis’ $900M radioligand deal | 2026-09-22 14:20 | [Source Link](https://news.google.com/rss/articles/CBMiigFBVV95cUxOVEE4MHFFYkMxTnBwUmdKdkZvbnN6ZzFMLVE4NmtZVVJSTmZrRVhqZHZIODNNd2dyOVhxNm9fRFUteS13c1VDRE9RSGFzd3RodDB0UUNwdlozaWN3MUJHQ2NuYThaYUhEOE85bkdzWmZnMjRXYS1JQkNLYzFwSXdiT3p5OU9jMzZKWGc?oc=5) |
| reuters.com | Amgen's autoimmune drug succeeds in late-stage trial | 2026-09-22 14:20 | [Source Link](https://news.google.com/rss/articles/CBMivAFBVV95cUxPX25PclJ1Zk15TDJINlZ6LVhrSWdOcDJnandPUkpOZGxKLWJ2TGZQRzVHcUhOR25YX216SEFJZ2dLT21tdjZrNUI3MkVaMjVCX2ZiOUtTeHh1QXpyU3B4RVdkcmF2U01Bbk9vcXlsa1RFSUNzejFpc2plYmttZGFvcFZJZXRudFhxYkRwVmpnYjdhaDVBbTFscU03bHZ1STN2WTNFZndDZm02MEY0dWJIZXBFVUl2OEpzNXBPWA?oc=5) |
| Fierce Biotech | Amgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 win | 2026-09-22 14:20 | [Source Link](https://news.google.com/rss/articles/CBMirgFBVV95cUxNSklwVHRGU1VlejR0YkhHdWk4SC1samVyUmVUcWpDeTV5eEoyM0FoQk55c091VEVaMkFvNjZrM3FKQ0ZWT3VCV3RJMXAzU0lxMFdOOTQ5X3FXVnp4REd3U21DWVBNdEJGeDNzLXFCOHhrR0habUN5dkVzbUJKcll0RjIzTDlwMXQydWlnbkNldmp4Q2E0czF5WW45Nk5jaWNpWVZuTTAwLXNENG9FRWc?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-09-22/amgen-s-horizon-acquired-fusion-protein-eases-sjogren-s-severity-in-ph-3-win*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*